4:32 PM ET
10-Q
Financial Results
Connect Biopharma Holdings Q3 2026 Results: Net Loss of $16.1M, Loss Narrows
Connect Biopharma reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to $40.4 million in the prior year, primarily driven by a significant increase in research and development expenses. Total assets decreased from $56.1 million at year-end 2025 to $27.8 million as of September 30, 2026, reflecting the company's continued cash burn for clinical operations.
- Key figure
- Net loss $16.1M